弥漫性胶质瘤免疫表型与IDH突变的相关性
研究分析43例WHO II/III级胶质瘤和14例IDH突变型胶质母细胞瘤的TIL浸润与PD-L1表达,并与117例IDH野生型胶质母细胞瘤数据比较,同时评估TCGA数据库中677例弥漫性胶质瘤的PD-L1基因表达。结果显示IDH野生型胶质瘤的TIL浸润和PD-L1表达显著高于IDH突变型,PD-L1基因启动子甲基化水平差异可能参与机制。
要点
- 约半数WHO II/III级胶质瘤可见TIL浸润和PD-L1表达。
- IDH野生型胶质瘤的TIL浸润和PD-L1表达显著高于IDH突变型。
- IDH突变型胶质瘤PD-L1基因启动子甲基化水平高于IDH野生型。
核心结论
- 弥漫性胶质瘤的免疫微环境与IDH突变状态相关,IDH野生型胶质瘤呈现更显著的TIL浸润和更高的PD-L1表达,机制上可能部分源于PD-L1基因启动子甲基化水平差异。
研究设计与样本
- 分析43例WHO II/III级胶质瘤(39例IDH突变型,4例IDH野生型)和14例IDH突变型胶质母细胞瘤的TIL(CD3+;PD1+)浸润及PD-L1表达,并与既往发表的117例IDH野生型胶质母细胞瘤数据比较。
- 在TCGA数据库中评估677例II-IV级弥漫性胶质瘤的PD-L1基因表达水平。
主要发现
- 约半数WHO II/III级胶质瘤中观察到TIL浸润和PD-L1表达。
- 在所有II-IV级病例中(n=174),IDH野生型状态与显著更高的TIL浸润和PD-L1表达相关(P < 0.001)。
- 在胶质母细胞瘤队列中(n=131),IDH野生型状态与显著更高的TIL浸润和PD-L1表达相关(P < 0.001)。
- TCGA低级别胶质瘤队列中(N=516),IDH野生型样本的PD-L1基因表达水平显著高于IDH突变型样本(P = 1.933e-11)。
- TCGA胶质母细胞瘤队列中(N=161),IDH野生型样本的PD-L1基因表达水平显著高于IDH突变型样本(P < 0.009)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tumor infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) are targets of immune checkpoint inhibitors. METHODS: Forty-three World Health Organization (WHO) grade II/III gliomas (39 IDH-mutant [mut], 4 IDH-wildtype [wt]) and 14 IDH-mut glioblastomas (GBM) were analyzed for TIL (CD3+; PD1+) infiltration and PD-L1 expression. Results were compared with the data of a previously published series of 117 IDH-wt glioblastomas. PD-L1 gene expression levels were evaluated in 677 diffuse gliomas grades II-IV from The Cancer Genome Atlas (TCGA) database. RESULTS: TIL and PD-L1 expression were observed in approximately half of WHO grade II/III gliomas. IDH-wt status was associated with significantly higher TIL infiltration and PD-L1 expression among all (grades II-IV) cases (n = 174, P < 0.001) and within the cohort of glioblastomas (n = 131, P < 0.001). In low-grade glioma (LGG) and glioblastoma cohorts of TCGA, significantly higher PD-L1 gene expression levels were evident in IDH-wt compared with IDH-mut samples (LGG: N = 516; P = 1.933e-11, GBM: N = 161; P < 0.009). Lower PD-L1 gene expression was associated with increased promoter methylation (Spearman correlation coefficient -0.36; P < 0.01) in the LGG cohort of TCGA. IDH-mut gliomas had higher PD-L1 gene promoter methylation levels than IDH-wt gliomas (P < 0.01). CONCLUSIONS: The immunological tumor microenvironment of diffuse gliomas differs in association with IDH mutation status. IDH-wt gliomas display a more prominent TIL infiltration and higher PD-L1 expression than IDH-mut cases. Mechanistically this may be at least in part due to differential PD-L1 gene promoter methylation levels. Our findings may be relevant for immune modulatory treatment strategies in glioma patients.
引用
- Berghoff AS, Kiesel B, Widhalm G, et al. Correlation of immune phenotype with IDH mutation in diffuse glioma. Neuro Oncol. 2017. PMID: 28531337. doi:10.1093/neuonc/nox054
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。